FDA orphan drug designations for lysosomal storage disorders – a cross-sectional analysis

Статус орфанных лекарственных средств FDA для лечения лизосомных болезней накопления: поперечный анализ
Eugen Mengel, Konstantin Mechler, Georg Friedrich Hoffmann, Markus Ries, Stefan Kölker, Christian Staufner, Sven F. Garbade, Matthias Zielonka
2020-04-08

FDA orphan drug designationsenzyme replacement therapygene therapylysosomal storage disorderspharmacological chaperones
PURPOSE: To provide a quantitative clinical-regulatory insight into the status of FDA orphan drug designations for compounds intended to treat lysosomal storage disorders (LSDs). METHODS: Assessment of the drug pipeline through analysis of the FDA database for orphan drug designations with descriptive and comparative statistics. RESULTS: Between 1983 and 2019, 124 orphan drug designations were granted by the FDA for compounds intended to treat 28 lysosomal storage diseases. Orphan drug designations focused on Gaucher disease (N = 16), Pompe disease (N = 16), Fabry disease (N = 10), MPS II (N = 10), MPS I (N = 9), and MPS IIIA (N = 9), and included enzyme replacement therapies, gene therapies, and small molecules, and others. Twenty-three orphan drugs were approved for the treatment of 11 LSDs. Gaucher disease (N = 6), cystinosis (N = 5), Pompe disease (N = 3), and Fabry disease (N = 2) had multiple approvals, CLN2, LAL-D, MPS I, II, IVA, VI, and VII one approval each. This is an increase of nine more approved drugs and four more treatable LSDs (CLN2, MPS VII, LAL-D, and MPS IVA) since 2013. Mean time between orphan drug designation and FDA approval was 89.7 SD 55.00 (range 8-203, N = 23) months. CONCLUSIONS: The drug development pipeline for LSDs is growing and evolving, with increased focus on diverse small-molecule targets and gene therapy. CLN2 was the first and only LSD with an approved therapy directly targeted to the brain. Newly approved products included "me-too"-enzymes and innovative compounds such as the first pharmacological chaperone for the treatment of Fabry disease.
1
Between 1983 and 2019, the FDA granted 124 orphan drug designations for compounds targeting 28 lysosomal storage diseases.
2
CLN2 became the first and only lysosomal storage disease with an FDA-approved therapy directly targeting the brain, while Fabry disease received the first pharmacological chaperone.
3
Compared with 2013, approvals increased by nine drugs and expanded treatment availability to four additional diseases: CLN2, MPS VII, LAL-D, and MPS IVA.
4
Designations concentrated on Gaucher and Pompe diseases (16 each), followed by Fabry disease and MPS II (10 each), MPS I and MPS IIIA (9 each).
5
The development landscape included both follow-on enzyme therapies and innovative compounds, indicating a growing and diversifying LSD pipeline.
6
The mean interval from orphan designation to FDA approval was 89.7 months, ranging from 8 to 203 months; the pipeline increasingly emphasized small molecules and gene therapies.
7
Twenty-three orphan drugs were approved for 11 lysosomal storage diseases, including multiple approvals for Gaucher disease, cystinosis, Pompe disease, and Fabry disease.

FDA orphan drug designations and approvals for compounds intended to treat lysosomal storage disorders

The status, distribution, therapeutic modalities, and development timelines of the LSD orphan-drug pipeline

Publication Details
Publication Date
2020-04-08
Journal
Publisher
ISSN
Cited by
41
Access Type
Author Information
Authors
Eugen Mengel
Konstantin Mechler
Georg Friedrich Hoffmann
Markus Ries
Stefan Kölker
Christian Staufner
Sven F. Garbade
Matthias Zielonka
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%